Opinions
Paul Harris, CFA
Teva Pharmaceutical
TEVA-N
BUY
Dec 30, 2016
$36.250
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology
pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology
pharmaceutical
DON'T BUY
Primarily a generic company, but a much more diversified generic company. They have things in respiratory, oncology, women’s health, etc. The stock has fallen off and is trading at about 6X earnings with a free cash flow yield of about 13%. A great dividend yield of almost 4%. This is a strong franchise in generics, and nobody can compete with them. They have some things in the pipeline that are very good, which will come to fruition and help them. Healthcare is the only sector that has underperformed this year because people are worried about overpricing. With their acquisition, there is also a change in management, so there is a little uncertainty. You should do very well with this over the next several years.